Connect Biopharma Announces Promising Phase 2 Data for Rademikibart in Asthma and COPD, with Topline Results Expected in 1H 2026

Reuters

09/29

<a href="https://laohu8.com/S/CNTB">Connect Biopharma</a> Announces Promising Phase 2 Data for Rademikibart in Asthma and COPD, with Topline Results Expected in 1H 2026

Connect Biopharma Holdings Limited has announced new data supporting its investigational anti-interleukin-4-receptor alpha (IL-4Rα) antibody, rademikibart, at the European Respiratory Society (ERS) Congress 2025. The data demonstrated rapid and significant improvements in lung function and asthma control among patients, with the greatest benefits observed in those with elevated baseline levels of type 2 inflammatory markers. The results also showed a significant reduction in annualized exacerbations in patients with one or more elevated type 2 inflammatory markers at baseline. These findings support the ongoing Phase 2 Seabreeze STAT studies evaluating rademikibart for acute exacerbations in asthma and COPD. Connect Biopharma expects to report topline data from these studies in the first half of 2026. The company has made the presentations available on its website under the publications and presentations section.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536355-en) on September 29, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2571336758"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571336758\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571336758?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571336758","market":"nz","top_or_hot":-1,"title":"Connect Biopharma Announces Promising Phase 2 Data for Rademikibart in Asthma and COPD, with Topline Results Expected in 1H 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a> Announces Promising Phase 2 Data for Rademikibart in Asthma and COPD, with Topline Results Expected in 1H 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Connect Biopharma Holdings Limited has announced new data supporting its investigational anti-interleukin-4-receptor alpha (IL-4Rα) antibody, rademikibart, at the European Respiratory Society (ERS) Congress 2025. The data demonstrated rapid and significant improvements in lung function and asthma control among patients, with the greatest benefits observed in those with elevated baseline levels of type 2 inflammatory markers. The results also showed a significant reduction in annualized exacerbations in patients with one or more elevated type 2 inflammatory markers at baseline. These findings support the ongoing Phase 2 Seabreeze STAT studies evaluating rademikibart for acute exacerbations in asthma and COPD. Connect Biopharma expects to report topline data from these studies in the first half of 2026. The company has made the presentations available on its website under the publications and presentations section.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536355-en) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Connect Biopharma Announces Promising Phase 2 Data for Rademikibart in Asthma and COPD, with Topline Results Expected in 1H 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConnect Biopharma Announces Promising Phase 2 Data for Rademikibart in Asthma and COPD, with Topline Results Expected in 1H 2026\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-29 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a> Announces Promising Phase 2 Data for Rademikibart in Asthma and COPD, with Topline Results Expected in 1H 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Connect Biopharma Holdings Limited has announced new data supporting its investigational anti-interleukin-4-receptor alpha (IL-4Rα) antibody, rademikibart, at the European Respiratory Society (ERS) Congress 2025. The data demonstrated rapid and significant improvements in lung function and asthma control among patients, with the greatest benefits observed in those with elevated baseline levels of type 2 inflammatory markers. The results also showed a significant reduction in annualized exacerbations in patients with one or more elevated type 2 inflammatory markers at baseline. These findings support the ongoing Phase 2 Seabreeze STAT studies evaluating rademikibart for acute exacerbations in asthma and COPD. Connect Biopharma expects to report topline data from these studies in the first half of 2026. The company has made the presentations available on its website under the publications and presentations section.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536355-en) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDLhnd0Q:1","article_id":"2571336758","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571336758","pubTimestamp":1759150841,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Connect Biopharma Announces Promising Phase 2 Data for Rademikibart in Asthma and COPD, with Topline Results Expected in 1H 2026. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire  on September 29, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技","CNTB":"康乃德生物医药","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Connect Biopharma宣布Rademikibart治疗哮喘和COPD的有希望的2期数据，预计将于2026年上半年获得主要结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTB":0.9,"NDAQ":0.9},"content_text":"Connect Biopharma Announces Promising Phase 2 Data for Rademikibart in Asthma and COPD, with Topline Results Expected in 1H 2026\n    \n\n        Connect Biopharma Holdings Limited has announced new data supporting its investigational anti-interleukin-4-receptor alpha (IL-4Rα) antibody, rademikibart, at the European Respiratory Society (ERS) Congress 2025. The data demonstrated rapid and significant improvements in lung function and asthma control among patients, with the greatest benefits observed in those with elevated baseline levels of type 2 inflammatory markers. The results also showed a significant reduction in annualized exacerbations in patients with one or more elevated type 2 inflammatory markers at baseline. These findings support the ongoing Phase 2 Seabreeze STAT studies evaluating rademikibart for acute exacerbations in asthma and COPD. Connect Biopharma expects to report topline data from these studies in the first half of 2026. The company has made the presentations available on its website under the publications and presentations section.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536355-en) on September 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}